Ana María López to lead medical oncology at Sidney Kimmel

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Ana María López joined the Sidney Kimmel Cancer Center–Jefferson Health as the vice chair of medical oncology and chief of cancer services at the Sidney Kimmel Cancer Center–Washington Township.

López comes from the Huntsman Cancer Institute in Salt Lake City, where she was director of Cancer Health Equality, in addition to associate VP for Health Equity and Inclusion at the University of Utah Health; associate director of Collaboration and Engagement Services at the Utah Center for Clinical and Translational Sciences; and professor of medicine at UU School of Medicine.

She is an expert in breast and gynecological cancers, integrative medicine, telehealth and cancer disparities. Currently she is president of the Philadelphia-based American College of Physicians, which is the largest medical specialty organization in the United States. Additionally, her strong commitment to cancer disparities is reflected in her leadership of the American Society of Clinical Oncology committee on cancer disparities.

López will be based out of SKCC in Center City until the New Jersey site is remodeled. Once she moves into the new site, she will continue to collaborate with research and physician teams throughout the Sidney Kimmel Cancer Center Network and will still spend some days in Center City.

Table of Contents

YOU MAY BE INTERESTED IN

In his first sit-down interview since beginning his role as FDA commissioner 17 days earlier, Marty Makary, a former Johns Hopkins surgeon and the only Trump pick for HHS whose confirmation received Democratic support, said he would speed up approvals for rare-disease treatments by reducing reliance on animal testing and shifting towards organoids and computational models. 
The American Cancer Society’s recent report on the increasing incidence rates of colorectal cancer in young adults once again rang an alarm bell for adults over 45 to get checked, especially if they are having symptoms. But as an oncologist with more than 40 years of experience, I also believe that this should be a clarion call to scientists and researchers, and for regulators at the FDA.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login